ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,738.52
-1.78%
US Tech 100
19,620.80
-2.29%
다우존스 지수
42,579.08
-0.99%
Bitcoin
87,922.92
-2.23%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NYSE

  6. GSK plc (GSK) 시세

GSK plc

GSK plc (GSK)

Goldseek Resources Inc
Gsk Plc
39.30
0.49
(1.26%)
마감 07 3월 6:00AM
15분 지연
39.4575
0.1575
(0.40%)
시간외 거래: 9:59AM
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
39.4575
매수가
-
매도가
-
거래량
5,511,194
38.60 일간 변동폭 39.42
31.715 52주 범위 45.925
market_cap
81.794B
전일 종가
38.81
개장가
38.61
최근 거래 시간
100
@
39.4575
(formt)
마지막 거래 시간
재정 규모
US$ 215,715,865
VWAP
39.1414
평균 볼륨(3m)
4,582,051
발행 주식
2,072,972,741
배당수익률
4.06%
주가수익률
12.10
주당순이익(EPS)
1.24
매출
31.38B
순이익
2.58B

GSK plc 정보

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines.

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.gsk.com
본부
London, Gbr
설립됨
-
GSK plc is listed in the Pharmaceutical Preparations sector of the 뉴욕 증권거래소 with ticker GSK. The last closing price for GSK was US$38.81. Over the last year, GSK shares have traded in a share price range of US$ 31.715 to US$ 45.925.

GSK currently has 2,072,972,741 shares in issue. The market capitalisation of GSK is US$80.45 billion. GSK has a price to earnings ratio (PE ratio) of 12.10.

GSK (GSK) 옵션 플로우 요약

전체 옵션 플로우 보기

전체 흐름

강세

순 프리미엄

30k

Calls / Puts

100.00%

매수 / 매도

100.00%

OTM / ITM

0.00%

Sweeps 비율

0.00%

GSK 최신 뉴스

추가 뉴스

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
27 2월 2025
GSK (1.26%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
27 2월 2025
GSK (1.26%)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Edgar (US Regulatory)
12 2월 2025
GSK (1.26%)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
12.38756.4405179390337.0739.457536.99529758737.89574134DR
41.93755.1639125799637.5239.457535.53536329337.10392937DR
125.137514.969405594434.3239.457531.715458205135.42880148DR
26-4.3325-9.8938113724643.7944.1931.715513726936.63122185DR
52-2.9225-6.8959414818342.3845.92531.715425390538.64149259DR
156-0.2225-0.56073588709739.6846.9728.465444691137.66347407DR
260-2.1825-5.2413544668641.6446.9728.465444123738.24179657DR

GSK - Frequently Asked Questions (FAQ)

What is the current GSK share price?
The current share price of GSK is US$ 39.4575
How many GSK shares are in issue?
GSK has 2,072,972,741 shares in issue
What is the market cap of GSK?
The market capitalisation of GSK is USD 80.45B
What is the 1 year trading range for GSK share price?
GSK has traded in the range of US$ 31.715 to US$ 45.925 during the past year
What is the PE ratio of GSK?
The price to earnings ratio of GSK is 12.1
What is the cash to sales ratio of GSK?
The cash to sales ratio of GSK is 0.99
What is the reporting currency for GSK?
GSK reports financial results in GBP
What is the latest annual turnover for GSK?
The latest annual turnover of GSK is GBP 31.38B
What is the latest annual profit for GSK?
The latest annual profit of GSK is GBP 2.58B
What is the registered address of GSK?
The registered address for GSK is 79 NEW OXFORD STREET, LONDON, WC1A 1DG
What is the GSK website address?
The website address for GSK is www.gsk.com
Which industry sector does GSK operate in?
GSK operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
MYEMyers Industries Inc
US$ 12.4895
(28.23%)
1.37M
SUPSuperior Industries International
US$ 2.01
(20.36%)
463.03k
MSCStudio City International Holdings Limited
US$ 3.30
(19.57%)
28.56k
SSTSystem1 Inc
US$ 0.5602
(19.22%)
188.96k
ANROAlto Neuroscience Inc
US$ 3.94
(16.57%)
585.9k
PNSTPinstripes Holdings Inc
US$ 0.0473
(-69.29%)
1.31M
VGVenture Global Inc
US$ 9.10
(-36.05%)
44.43M
ONLOrion Office REIT Inc
US$ 2.7195
(-29.36%)
3.99M
MEIMethode Electronics Inc
US$ 7.00
(-28.72%)
1.56M
BKSYBlackSky Technology Inc
US$ 9.98
(-24.39%)
3.85M
FFord Motor Company
US$ 9.61
(-0.41%)
134.03M
BTEBaytex Energy Corporation
US$ 1.98
(0.00%)
68.95M
NUNu Holdings Ltd
US$ 10.65
(-2.02%)
63.9M
BACBank of America Corporation
US$ 41.46
(-1.96%)
57.62M
BBAIBigBear ai Holdings Inc
US$ 4.225
(-11.98%)
55.52M

GSK Discussion

게시물 보기
Monksdream Monksdream 6 월 전
GSK up and down but mostly up
👍️0
Monksdream Monksdream 1 년 전
GSK new 52 week high
👍️0
Monksdream Monksdream 1 년 전
GSK new 52 week high
👍️0
Monksdream Monksdream 1 년 전
GSK new 52 week high
👍️ 1
1jas 1jas 2 년 전
has anybody here seen that enzolytics pharm announced that they have a cure for hiv/aids yesterday.
👍️0
MrHankey MrHankey 2 년 전
Does the name Christian Lamarco (www.culperresearch.com) mean anything to you?
If not, you should know that this "activist investor" (aka "short") has requested through FOIA from the FDA for the below information. Prepare for a hit piece and a stock drop.

"Requesting copies of the letter and/or all communications from the FDA to GSK requesting the withdrawal of GSK's Blenrep from the market in the US, as widely reported in November 2022."

https://www.fda.gov/media/170006/download
👍️0
Magnum7419 Magnum7419 2 년 전
i am in 100@ 34.56 :)
👍️0
Magnum7419 Magnum7419 2 년 전
GSK #1 pick!!
👍️0
jondoeuk jondoeuk 2 년 전
Post hoc analysis shows that biomarker correlates with response to NY-ESO-1 TCR-T cells in patients with synovial sarcoma https://www.nature.com/articles/s41467-022-32491-x
👍️0
BottomBounce BottomBounce 3 년 전
$GSK Total Debt is $22.11 Billion // $8.00 should be trading
👍️0
rosemountbomber rosemountbomber 3 년 전
Anyone know how we will calculate our cost basis in Haleon?
👍️0
ruke ruke 3 년 전
So, why shares aren't realy mooning in pre-market? Isn't that strange?
👍️0
jondoeuk jondoeuk 3 년 전
Complete Responses in 100% of dMMR Rectal Cancer With Neoadjuvant PD-1 Inhibition https://www.medpagetoday.com/meetingcoverage/asco/99071
👍️0
jondoeuk jondoeuk 3 년 전
Lete-Cel ASCO data https://www.cgtlive.com/view/lete-cel-exhibits-anti-tumor-activity-long-median-pfs-patients-myxoid-round-cell-liposarcoma

👍️0
jondoeuk jondoeuk 3 년 전
The company has updated the master protocol for their next generation constructs to include a third arm with GSK4427296 https://clinicaltrials.gov/ct2/show/NCT04526509

This uses LYEL's Epi-R https://lyell.com/our-platforms
👍️0
4MVault 4MVault 3 년 전
GSK Should buy ATOS
👍️0
jondoeuk jondoeuk 4 년 전
New NY-ESO-1 TCR-T data https://jitc.bmj.com/content/7/1/276

From it: ''These data provide an initial rationale as to how tumors with histologies resistant to checkpoint blockade can be successfully targeted with adoptive T-cell therapy. Furthermore, these data are the first to demonstrate successful infiltration of solid tumors by SPEAR T cells, which are able to kill tumor cells. Our data also suggest that antigen loss or alterations in the expression of antigen processing proteins are not primary mechanisms of resistance. Moreover, the therapeutic efficacy may be enhanced through use of a high dose fludarabine-containing preparative lymphodepletion regimen, by promoting greater engraftment at the tumor site, and through modulation of TAM.''
👍️0
jondoeuk jondoeuk 4 년 전
They have shared some preclinical data https://www.sec.gov/Archives/edgar/data/1806952/000119312521172500/d168165ds1.htm
👍️0
jondoeuk jondoeuk 4 년 전
Preclinical data from another group: ''Hepatocellular carcinoma (HCC) is responsible for most of primary liver cancer cases and is the sixth most common cancer in the world with a general 5 year survival rate of 18% due to lack of effective therapy. Adoptive T-cell therapy (ACT) with T-cell receptor–engineered T-cell (TCR-T) against HCC-associated antigen a-fetoprotein (AFP), can redirect human T cells to recognize and kill HCC tumor cells.

However, the clinical efficacy of TCR-T therapy is dependent on the proper expansion, in vivo persistence of T cells that is markedly reduced due to exhaustion-associated dysfunction, and activation induced cell death. To improve persistence of TCR-T cells without modifying TCR affinity, we engineered TCR-T cells to overexpress c-Jun, an AP-1 transcription factor associated with T cell development and activation. In this study, we showed that TCR-T cells overexpressing c-Jun have enhanced expansion capacity in culture, improved cytokine production against HepG2 tumor cells without altering their cytotoxic potential.

Interestingly TCR-T cells overexpressing c-Jun showed resistance to activation induced cell death with decreased expression of inhibitory receptors after stimulation with HepG2 tumor cells. Thus, c-Jun overexpression could be a potential therapeutic agent to enhance the anti-tumor efficacy of TCR-T cells against HCC.''

https://virtual.aai.org/aai/2021/virtual-immunology-2021/317351/mohamed.hussein.the.role.of.c-jun.in.enhancing.tcr-t.function.in.treatment.of.html
👍️0
jondoeuk jondoeuk 4 년 전
Some more info https://lyell.com/our-platforms

👍️0
stillness0007 stillness0007 4 년 전
GSK V TEVA question. The panel of judges heard the case on Feb 23rd. Am I right to understand, usually a decision is made 3-4 months after that? Cause some are saying by end of 2022, which makes no sense to me.
👍️0
testing4covid testing4covid 4 년 전
Achiko AG: The One Ecosystem that Takes a ‘Swiss Cheese’ Approach to COVID-19

Great article on an upcoming testing technology:

https://sponsored.bloomberg.com/news/sponsors/features/next-tech-stock/the-next-big-thing-in-health-tech/?adv=33197&prx_t=wmcGAAAAAAUk0NA&prx_ro=s&sref=GS2dzBte



👍️0
whytestocks whytestocks 4 년 전
Breaking News: $GSK Investors Wish They Could Vote These 2 Healthcare CEOs Out

One of the best things about a democracy is getting to vote out representatives who let us down. As shareholders, it's much harder to express dissatisfaction in management without just selling shares, since you may really like the business despite management.  But some investors might ...

Read the whole news GSK - Investors Wish They Could Vote These 2 Healthcare CEOs Out
👍️0
jondoeuk jondoeuk 4 년 전
Decitabine has been shown to induce cancer-testis antigen expression https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0139221
👍️0
jondoeuk jondoeuk 4 년 전
SITC

Decitabine gene modulation sensitizes human non–small cell lung cancer (NSCLC) to NY-ESO-1 TCR immunotherapy (letetresgene autoleucel; GSK3377794) in vivo

Modeling the efficacy of NY-ESO-1 TCR T cells (letetresgene autoleucel; GSK3377794) in patients with synovial sarcoma: correlations of response with transduced cell kinetics and biomarkers

Final analysis of the Phase 1 trial of NY-ESO-1–specific T-cell receptor (TCR) T-cell therapy (letetresgene autoleucel; GSK3377794) in patients with advanced synovial sarcoma (SS)
👍️0
jondoeuk jondoeuk 4 년 전
Going forward, I would like them to transduce half of the CD4+ T-cells with an NY-ESO-1 specific MHC II restricted TCR [1], and the other half to co-express a CD8a. Combining both CD4+ and CD8+ can induce bystander killing of antigen-negative cancer cells [2,3]. Also, some of the CD4+ can show tumoricidal activity by their own means irrespective of MHC II expression [4-7].

Refs:
1 https://www.nejm.org/doi/full/10.1056/nejmoa0800251
2 https://rupress.org/jem/article/207/11/2469/40645/Bystander-killing-of-cancer-requires-the
3 https://www.nature.com/articles/srep14896
4 https://cancerres.aacrjournals.org/content/70/21/8368.long
5 https://rupress.org/jem/article/154/3/952/49262/Eradication-of-disseminated-murine-leukemia-by
6 https://rupress.org/jem/article/207/3/637/40473/Tumor-reactive-CD4-T-cells-develop-cytotoxic
7 https://www.cell.com/immunity/fulltext/S1074-7613(00)80218-6
👍️0
jondoeuk jondoeuk 4 년 전
Lyell plan to use defined cell populations [1], improve ex vivo expansion [2-4], and a novel co-stim [5].

Refs:
1 https://www.nature.com/articles/leu2015247
2 https://www.sciencedirect.com/science/article/abs/pii/S1535610820302543
3 https://cancerres.aacrjournals.org/content/75/2/296.long
4 https://link.springer.com/article/10.1007%2Fs00262-012-1378-2
5 https://www.nature.com/articles/s41586-019-1805-z
👍️0
jondoeuk jondoeuk 4 년 전
Hopefully, trials testing these improvements will start early next year https://www.fiercebiotech.com/biotech/gsk-taps-lyell-immunopharma-to-take-cell-therapy-to-next-level
👍️0
jondoeuk jondoeuk 4 년 전
A new trial testing the NY-ESO-1 TCR-T cell therapy product [1] which either co-expresses a CD8a [2] or dnTGFßRII [2].

Refs:
1 https://clinicaltrials.gov/ct2/show/NCT04526509
2 (Some of the R&D was conducting with ADAP) https://www.adaptimmune.com/our-company/perspectives/detail/1153/jon-silk-talks-about-our-next-generation-research
👍️0
MustBeTheTruth MustBeTheTruth 5 년 전
Better Development Tools for a New Golden Era of Psychopharmacology

https://www.thecannabisinvestor.ca/better-development-tools-for-a-new-golden-era-of-psychopharmacology/
👍️0
T695 T695 5 년 전
Calls might sky rocket tomorrow
👍️0
T695 T695 5 년 전
Calls for next month
👍️0
BottomBounce BottomBounce 5 년 전
Trump promises Cincinnati rally that US will end AIDS epidemic and find a cure for childhood cancer 'very shortly'

https://www.businessinsider.com/trump-cincinnati-promises-cure-cancer-and-aids-very-shortly-2019-8
👍️0
BottomBounce BottomBounce 5 년 전
$GSK Democratic-run House approves its $3 trillion relief measure in vote late Friday https://www.marketwatch.com/story/next-coronavirus-aid-package-expected-to-become-reality-in-june-at-the-earliest-as-house-prepares-to-pass-its-bill-on-friday-2020-05-15?mod=mw_more_headlines
👍️0
BottomBounce BottomBounce 5 년 전
Here's Why Investors Should Follow Sanofi $SNY and GlaxoSmithKline's $GSK New #Coronavirus #COVID19
Collaboration


https://www.fool.com/investing/2020/04/30/heres-why-investors-should-follow-sanofi-and-glaxo.aspx
👍️0
BottomBounce BottomBounce 5 년 전
**** BREAKING HIV $GSK <<<< Drug giant GSK today declared a major breakthrough on a new HIV treatment it was trialling in patients that could prevent the spread of the disease. https://www.standard.co.uk/business/drug-giant-gsk-sees-major-breakthrough-on-hiv-treatment-a4442996.html
👍️0
Nebuchadnezzar Nebuchadnezzar 5 년 전
GSK-especially now in current market turmoil $35 looks XTRA tasty
👍️0
BottomBounce BottomBounce 5 년 전
Sci-B-Vac data is in December. That's the drug beating $GSK's Engerix-B

The infection prevention rate for $VBIV 91.4% for Sci-B-Vac

The infection prevention rate for $GSK 76.5% for Engerix-B
👍️0
BottomBounce BottomBounce 5 년 전
$VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK -2.8%) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.
👍️0
BottomBounce BottomBounce 5 년 전
$VBIV VBI Vaccines will collaborate with GlaxoSmithKline ( $GSK ) in a Phase 1/2a clinical trial evaluating its therapeutic vaccine candidate VBI-1901 in patients with recurrent glioblastoma (GBM) (brain tumor). It plans to add an additional arm to the open-label study to assess the combination of VBI-1901 and Glaxo's AS01B adjuvant that it uses in its Shingrix shingles vaccine.

Part B of the trial will now be two arms, one evaluating VBI-1901 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) and the other with AS01B, in 20 first-recurrent GBM patients. Enrollment of the first 10 participants should be initiated next quarter.

https://seekingalpha.com/news/3498284-vbi-vaccines-teams-glaxo-therapeutic-cancer-vaccine-shares-10-percent
👍️0
BottomBounce BottomBounce 5 년 전
$GSK and $VBIV VBI Vaccines teams up with Glaxo on therapeutic cancer vaccine https://seekingalpha.com/news/3498284-vbi-vaccines-teams-glaxo-therapeutic-cancer-vaccine-shares-10-percent
👍️0
Robbinhood101 Robbinhood101 5 년 전
Watch this one go up with Tesaro approval.
👍️0
I Need Money I Need Money 5 년 전
Certainly a great LONG term hold. ;)
👍️0
Don'tDrinkTheKoolAid Don'tDrinkTheKoolAid 5 년 전
YIKES haha nice up tick with a great divvy.
👍️0
I Need Money I Need Money 5 년 전
$41.99 now. :)
👍️0
Don'tDrinkTheKoolAid Don'tDrinkTheKoolAid 6 년 전
Yep 39 now with 5% divvy I don't own it now :(!
👍️0
DewDiligence DewDiligence 6 년 전
GSK, PFE form consumer-health JV: #msg-145552190.
👍️0
Dhubbard5 Dhubbard5 6 년 전
I agree with your theory completely make total sense.
👍️0
debunker1 debunker1 7 년 전
Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.

👍️0
Don'tDrinkTheKoolAid Don'tDrinkTheKoolAid 7 년 전
Buy anything below 36 not much down side risk.
👍️0

최근 히스토리

NYSE
GSK
GSK
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지